NCT04421222 - Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

December 3, 2024

Conditions

Prostate Cancer

Interventions

DRUG

EPI-7386 (QD)

Once daily oral dose of EPI-7386

DRUG

EPI-7386 (BID)

Twice daily oral dose of EPI-7386

DRUG

Abiraterone acetate

Once daily dose of abiraterone acetate

DRUG

Apalutamide

Once daily dose of apalutamide

Trial Locations (9)

Memorial Sloan Kettering Cancer Center, New York

Great Lakes Cancer Center, Buffalo

Winship Cancer Institute of Emory University, Atlanta

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie

Washington University School of Medicine in St. Louis, St Louis

Comprehensive Cancer Center of NV Las Vegas, Las Vegas

Massachusetts General Hospital, Boston

BC Cancer, Vancouver

Centre hospitalier de l'Université de Montréal, Montreal